{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daunorubicin&page=38",
    "query": {
      "intervention": "daunorubicin",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1299,
    "total_pages": 130,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daunorubicin&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daunorubicin&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T10:46:30.098Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05558124",
      "title": "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Vyxeos",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-02-16",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05558124"
    },
    {
      "nct_id": "NCT00194779",
      "title": "Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-negative Breast Cancer",
        "Estrogen Receptor-positive Breast Cancer",
        "HER2-positive Breast Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Progesterone Receptor-positive Breast Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine tartrate",
          "type": "DRUG"
        },
        {
          "name": "needle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2003-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2018-03-12",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00194779"
    },
    {
      "nct_id": "NCT00513188",
      "title": "Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "denileukin diftitox",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00513188"
    },
    {
      "nct_id": "NCT00176462",
      "title": "CINJALL: Treatment for Children With Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "aminopterin",
          "type": "DRUG"
        },
        {
          "name": "L-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunomycin",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "6-mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "6-thioguanine",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 60,
      "start_date": "2001-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 2,
      "location_summary": "Neptune City, New Jersey • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176462"
    },
    {
      "nct_id": "NCT00679029",
      "title": "Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-negative Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2008-05-02",
      "completion_date": "2010-11-18",
      "has_results": true,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679029"
    },
    {
      "nct_id": "NCT02710422",
      "title": "Miami Membrane for Potency (MMEP) Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Amniotic Membrane Placement",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EPIC 26",
          "type": "BEHAVIORAL"
        },
        {
          "name": "PSA Measurement",
          "type": "OTHER"
        },
        {
          "name": "Sexual History Inventory for Men",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "40 Years to 80 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2016-05-17",
      "completion_date": "2019-01-22",
      "has_results": true,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02710422"
    },
    {
      "nct_id": "NCT02668653",
      "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 539,
      "start_date": "2016-09-01",
      "completion_date": "2023-06-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02668653"
    },
    {
      "nct_id": "NCT00968253",
      "title": "RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Everolimus (RAD001)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Ara-C (Cytarabine)",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2009-11",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968253"
    },
    {
      "nct_id": "NCT05404945",
      "title": "Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Classical Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-07-26",
      "completion_date": "2027-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 3,
      "location_summary": "New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05404945"
    },
    {
      "nct_id": "NCT00666588",
      "title": "Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Childhood Acute Basophilic Leukemia",
        "Childhood Acute Eosinophilic Leukemia",
        "Childhood Acute Erythroleukemia (M6)",
        "Childhood Acute Megakaryocytic Leukemia (M7)",
        "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Childhood Acute Monoblastic Leukemia (M5a)",
        "Childhood Acute Monocytic Leukemia (M5b)",
        "Childhood Acute Myeloblastic Leukemia With Maturation (M2)",
        "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Childhood Acute Myelomonocytic Leukemia (M4)",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "idarubicin",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 52,
      "start_date": "2008-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-10-16T10:46:30.098Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00666588"
    }
  ]
}